BARDA, part of the US department of Health and Human Services’ Administration for Strategic Preparedness and Response, is funding development by Israel’s Redhill of Opaganib (see here previously) for the treatment of the Ebola virus. https://nocamels.com/2024/10/us-government-funding-development-of-israeli-ebola-treatment/

Opaganib, a novel, twice-daily, oral medication developed by Israel’s RedHill Biopharma (see here previously) delivered a statistically significant increase in survival time in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study https://www.israel21c.org/drug-shows-promise-in-treating-often-fatal-ebola-disease/